UPCOMING SESSIONS in ET

Tue, Oct 27, 2026

5:00 – 6:00 AM Bangkok

Partnering With Your Care Team: Make the Most of Clinic Visits Van Thai Click Here To Register

UPCOMING SESSIONS in ET

Tue, Oct 27, 2026 · 5:00 – 6:00 AM Bangkok

Partnering With Your Care Team: Make the Most of Clinic Visits

Van Thai

Click Here To Register

View all sessions

Clinical Trials and Research

asco

Amyloidosis: Novel Treatments Could Improve Poor Outcomes

Mar 17, 2026

Review Summarizes Mode of Action, Safety, and Efficacy of Eplontersen for hATTR

Read more

Mar 15, 2026

Cardiac Amyloidosis - Dr. Akif

Read more

Mar 13, 2026

Endomyocardial Biopsy Revisited: Diagnostic Value and Expanding Roles in Cardiac Amyloidosis

Read more

Oxford Academic

Mar 11, 2026

Therapy of amyloidosis: stabilizers and silencers

Read more

Mar 11, 2026

Blood phosphorylated tau elevation as a biomarker in immunoglobulin light chain and transthyretin amyloidosis

Read more

Mar 04, 2026

Therapeutic Efficacy and Safety Profile of Eplontersen in Hereditary Transthyretin‐Mediated Amyloidosis: A Systematic Review

Read more

amyloidosis

Mar 02, 2026

Possible treatments for ATTR-CM studied at MUSC, including some with stunning potential

Read more

Feb 25, 2026

Utilization and Prognosis of Cardiac Device Implantation in AL Versus ATTR Amyloidosis

Read more

Feb 21, 2026

How to monitor disease progression in ATTR amyloid cardiomyopathy: Implications for clinical practice and trial design

Read more

Feb 20, 2026

Rare c.302C>T TTR Variant Associated with Transthyretin Amyloidosis

Read more

Newsletter

RNAi Explained

Dr. Bersell explores RNA interference (RNAi) technology and its applications in treating ATTR-CM and ATTR-PN. Learn about mechanism of action, clinical evidence, and patient outcomes.

Expert Perspectives on Attruby®

Dr. Barry Trachtenberg and ATTR community members discuss Attruby™ (acoramidis), covering clinical data, patient perspectives, and treatment considerations.

Watch Discussion

Featured Trials